An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; Comparisons with wild-type Ad5 and a replication-defective adenovirus vector

Cancer Gene Therapy

Volumn 16, Issue 8, 2009, Pages 644-654

  Lichtenstein, D L ^a   Spencer, J F ^b   Doronin, K ^b,d   Patra, D ^b,e   Meyer, J M ^a   Shashkova, E V ^b,d   Kuppuswamy, M ^b   Dhar, D ^b   Thomas, M A ^b   Tollefson, A E ^b   Zumstein, L A ^c,f   Wold, W S M ^b   Toth, K ^b  

^a VirRx Inc   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Introgen Therapeutics Inc   (United States)

^d MAYO CLINIC   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PaxVax Inc   (United States)

Author keywords

Adenovirus; Mice; Oncolytic; Preclinical; Syrian hamster; Toxicology

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOVIRUS VECTOR; INGN 007; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LIVER INJURY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SYRIAN HAMSTER; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ANIMALS; BLOOD CELL COUNT; CELL LINE; CRICETINAE; ERYTHROPOIESIS; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MESOCRICETUS; MICE; MICE, INBRED C57BL; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

ADENOVIRIDAE; CRICETINAE; HUMAN ADENOVIRUS TYPE 5; MESOCRICETUS AURATUS; MUS;

EID: 67651121521     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.5     Document Type: Article

References (32)

1. Wold WSM, Horwitz MS. Adenoviruses. In: Knipe DM, Howley PM (eds). Field's Virology, 5th edn. Lippincott, Williams, & Wilkins: Philadelphia, PA, 2007: 2395-2436.
2. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 2006; 6: 697-708.
3. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007; 7: 285-301.
4. Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005; 32: 537-548.
5. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
6. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540.
7. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008; 25: 462-466.
8. Nemunaitis J, Edelman J. Selectively replicating viral vectors. Cancer Gene Ther 2002; 9: 987-1000.
9. Nemunaitis J, Vorhies JS, Pappen B, Senzer N. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther 2007; 14: 762-763.
10. Post LE. Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr Opin Invest Drugs 2002; 3: 1768-1772.
11. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002; 9: 979-986.
12. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM. Tumor-specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J Virol 2000; 74: 6147-6155.
13. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378-387.
14. Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75: 3314-3324.
15. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Therapy 2005; 12: 1608-1617.
16. Toth K, Djeha H, Ying BL, Tollefson AE, Kuppuswamy M, Doronin K et al. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 2004; 64: 3638-3644.
17. Shashkova EV, Spencer JF, Wold WSM, Doronin K. Human interferon-alpha expression increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007; 15: 598-607.
18. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
19. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
20. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146.
21. Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59: 2623-2628.
22. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
23. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Therapy 2003; 10: 935-940.
24. Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003; 14: 425-433.
25. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Therapy 2005; 12: 427-436.
26. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
27. Hjorth RN, Bonde GM, Pierzchala WA, Vernon SK, Wiener FP, Levner MH et al. A new hamster model for adenoviral vaccination. Arch Virol 1988; 100: 279-283.
28. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl AcadSci USA 2008; 105: 7293-7297.
29. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol 2006; 80: 3549-3558.
30. Mccoy RD, Davidson BL, Roessler BJ, Huffnagle GB, Janich SL, Laing TJ et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Human Gene Ther 1995; 6: 1553-1560.
31. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
32. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002; 76: 5711-5719.